Business Context and Reporting Period
Company: Proteon Therapeutics, Inc. (Note: Request metadata listed "Protara," but filing text confirms "Proteon")
Filing Type: Form 8-K (Current Report)
Date of Report: March 13, 2019
Reporting Period: Fourth Quarter and Full Year ended December 31, 2018
Status: Emerging Growth Company
Key Financial Metrics
This Form 8-K serves as a notification of the issuance of a press release regarding financial results. The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained in the attached press release (Exhibit 99.1), which is incorporated by reference but not included in the provided text.
Material Changes
The filing does not contain specific data to compare current period performance against prior periods. It solely references the announcement of results for the fourth quarter and full year 2018.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on March 13, 2019, announcing its financial results. The text of the press release is not included in this filing.
Legal Disclaimer: Information under Item 2.02 and the attached exhibit is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 13, 2019) for actual financial figures (revenue, net loss, cash position).
- Verify the company's cash runway and burn rate, as this is a pre-revenue biopharmaceutical company.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm the company's status as an Emerging Growth Company and any associated reporting exemptions.